Company intelligence / Profile preview
Huadao Biomedical
Shanghai, Shanghai, China
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Huadao Biomedical has successfully progressed its lead CAR-T candidate, HD337, into Phase 2 clinical trials for B-cell non-Hodgkin lymphoma, demonstrating significant efficacy and a manageable safety profile. The company is notably focused on a 'full-chain' industrialization model to reduce cell therapy costs.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Shanghai Ruijin HospitalShanghai Ninth People's Hospital
Beyond the preview
Go deeper on Huadao Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huadao Biomedical.